Pharma News Briefs

• SCOTUSblog reported on Wednesday that the Supreme Court has denied Pfizer's emergency application for relief from the Federal Circuit's ruling in the Norvasc case.  TheStreet.com also has an article on the Supreme Court's decision.
• On Tuesday, the Federal Circuit granted Mylan's motion for summary reversal of the district court decision that had found Pfizer's Norvasc patent valid and infringed by Mylan.  The Fed. Cir. also reversed and vacated a separate district court decision finding the Norvasc patent valid and infringed by Synthon.  Both decisions came without opinion.
• FDA Law Blog reports today that a provision of the FDA Revitalization Act will reform the citizen petition process.
• The Washington Post on Monday reported on continued wrangling between the DOJ and FTC on the legality of reverse payment settlements, such as the one in Joblove.
• Via SCOTUSblog, here is petitioner's supplemental brief in Joblove, responding to the Solicitor General's recommendation that the Court decline to hear the case.
• Barr Labs announced earlier this week that Barr and Lilly agreed to dismiss their litigation over Prozac Weekly.
• Kaisernetwork.org reports that the markup session for the Waxman-Schumer follow-on biologics bill has been delayed to June 20.  Supporters of the bill still hope to attach it to the FDA Revitalization Act and pass it into law this year.